Less than one in 10 patients that would benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it releases its first recommendations on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is urging broader and more equitable access to these injectable treatments.
Based on estimates, over two billion are projected to be obese by 2030 if no action is taken.
"The latest guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and ongoing treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major barriers to universal availability to the jabs that can assist patients in reducing considerable weight, says the body.
Weight-Loss Drug Supply Crisis
Despite the present most optimistic case, the supply of such drugs might only reach approximately 100 million people – under 10% of those who need them, as stated by the health organization.
The guideline encourages governments and firms to widen access, by approaches including licensing agreements.
A patent on a key compound – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
How Weight-Loss Jabs Function
The injections replicate a biological compound to reduce digestion speed, suppress the appetite and boost feelings of fullness so people reduce food intake.
People usually begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Evidence suggests users may put most of the weight back on after a year of stopping the drug, because their typical appetite come back.
To be overweight or obese increases your risk for experiencing health problems, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity impacts individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
